{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Paul MR"],"funding":["NICHD NIH HHS","NCATS NIH HHS"],"pagination":["e546-e549"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7216755"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(8)"],"pubmed_abstract":["<h4>Background</h4>Inotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells.<h4>Observations</h4>A 7-year-old boy with pre-B acute lymphoblastic leukemia in his second relapse was given 2 cycles of inotuzumab ozogamicin. He responded morphologically with a negative bone marrow evaluation. However, he relapsed in cycle 3 of therapy with a loss of CD22 expression on his lymphoblast population.<h4>Conclusion</h4>To our knowledge, this is the first published case of CD22 expression loss as a mechanism of therapy resistance for inotuzumab ozogamicin."],"journal":["Journal of pediatric hematology/oncology"],"pubmed_title":["Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance."],"pmcid":["PMC7216755"],"funding_grant_id":["TL1 TR001443","T32 HD087978"],"pubmed_authors":["Wong V","Paul MR","Aristizabal P","Kuo DJ"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.","description":"<h4>Background</h4>Inotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells.<h4>Observations</h4>A 7-year-old boy with pre-B acute lymphoblastic leukemia in his second relapse was given 2 cycles of inotuzumab ozogamicin. He responded morphologically with a negative bone marrow evaluation. However, he relapsed in cycle 3 of therapy with a loss of CD22 expression on his lymphoblast population.<h4>Conclusion</h4>To our knowledge, this is the first published case of CD22 expression loss as a mechanism of therapy resistance for inotuzumab ozogamicin.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-25T22:58:08.469Z","creation":"2020-11-04T08:04:24Z"},"accession":"S-EPMC7216755","cross_references":{"pubmed":["30807395"],"doi":["10.1097/mph.0000000000001440","10.1097/MPH.0000000000001440"]}}